Literature DB >> 10205003

Effects of propafenone on K currents in human atrial myocytes.

A Seki1, N Hagiwara, H Kasanuki.   

Abstract

1. The class Ic anti-arrhythmic agent, flecainide is known to inhibit the transient outward K current (Ito) selectively in human atrium. We studied the effects of propafenone, another class Ic antiarrhythmic agent, on K currents in human atrial myocytes using a whole-cell voltage-clamp method. 2. Propafenone inhibited both Ito and the sustained or ultra-rapid delayed rectifier K current (Isus or Ikur) evoked by depolarization pulses. The concentration for half-maximal inhibition (IC50) was 4.9 microM for Ito and 8.6 microM for Isus. Propafenone blocked Ito and Isus in a voltage- and use-independent fashion and accelerated the inactivation time constant of Ito [from 28.3 to 6.7 ms at 10 microM propafenone]. 3. The steady-state inactivation curve for Ito was unaffected by propafenone. Propafenone did not affect the initial current at depolarizing potentials, but it did produce a block that increased as a function of time after depolarization (time constant of 3.4 ms). This suggests that propafenone preferentially blocked Ito in the open state. 4. Propafenone had no significant effect on the rate at which Ito recovered from inactivation at -80 mV suggesting that propafenone dissociates rapidly from the channel. 5. The steady-state activation curve for Isus was not affected by propafenone. Propafenone slowed the time course of the onset of the Isus tail current. This suggests that propafenone blocked Isus in the open state. 6. The present results suggest that, unlike flecainide, propafenone blocks both Ito and Isus in human atrial myocytes in the open state at clinically relevant concentrations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10205003      PMCID: PMC1565895          DOI: 10.1038/sj.bjp.0702428

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues.

Authors:  Z G Wang; L C Pelletier; M Talajic; S Nattel
Journal:  Circulation       Date:  1990-07       Impact factor: 29.690

2.  Therapeutic efficacy and safety of oral propafenone for atrial fibrillation.

Authors:  J G Porterfield; L M Porterfield
Journal:  Am J Cardiol       Date:  1989-01-01       Impact factor: 2.778

3.  Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy.

Authors:  E L Pritchett; E A McCarthy; W E Wilkinson
Journal:  Ann Intern Med       Date:  1991-04-01       Impact factor: 25.391

4.  The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm.

Authors:  M J Suttorp; J H Kingma; E R Jessurun; L Lie-A-Huen; N M van Hemel; K I Lie
Journal:  J Am Coll Cardiol       Date:  1990-12       Impact factor: 24.094

5.  Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation.

Authors:  Z Wang; P Pagé; S Nattel
Journal:  Circ Res       Date:  1992-08       Impact factor: 17.367

6.  Mode of action of a new class IC drug (ORG 7797) against atrial fibrillation in conscious dogs.

Authors:  C Kirchhof; M Wijffels; J Brugada; J Planellas; M Allessie
Journal:  J Cardiovasc Pharmacol       Date:  1991-01       Impact factor: 3.105

7.  Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel.

Authors:  J Snyders; K M Knoth; S L Roberds; M M Tamkun
Journal:  Mol Pharmacol       Date:  1992-02       Impact factor: 4.436

8.  Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.

Authors:  S C Reimold; C O Cantillon; P L Friedman; E M Antman
Journal:  Am J Cardiol       Date:  1993-03-01       Impact factor: 2.778

9.  Differences in rate dependence of transient outward current in rabbit and human atrium.

Authors:  B Fermini; Z Wang; D Duan; S Nattel
Journal:  Am J Physiol       Date:  1992-12

10.  Background current in sino-atrial node cells of the rabbit heart.

Authors:  N Hagiwara; H Irisawa; H Kasanuki; S Hosoda
Journal:  J Physiol       Date:  1992-03       Impact factor: 5.182

View more
  5 in total

Review 1.  2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.

Authors:  Gyorgy Frendl; Alissa C Sodickson; Mina K Chung; Albert L Waldo; Bernard J Gersh; James E Tisdale; Hugh Calkins; Sary Aranki; Tsuyoshi Kaneko; Stephen Cassivi; Sidney C Smith; Dawood Darbar; Jon O Wee; Thomas K Waddell; David Amar; Dale Adler
Journal:  J Thorac Cardiovasc Surg       Date:  2014-06-30       Impact factor: 5.209

2.  Suppression of spontaneous ca elevations prevents atrial fibrillation in calsequestrin 2-null hearts.

Authors:  Michela Faggioni; Eleonora Savio-Galimberti; Raghav Venkataraman; Hyun Seok Hwang; Prince J Kannankeril; Dawood Darbar; Björn C Knollmann
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-02-03

3.  Cardiovascular pharmacology of K2P17.1 (TASK-4, TALK-2) two-pore-domain K+ channels.

Authors:  Ingo Staudacher; Claudius Illg; Sam Chai; Isabelle Deschenes; Sebastian Seehausen; Dominik Gramlich; Mara Elena Müller; Teresa Wieder; Ann-Kathrin Rahm; Christina Mayer; Patrick A Schweizer; Hugo A Katus; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-14       Impact factor: 3.000

4.  Computational Modeling for Antiarrhythmic Drugs for Atrial Fibrillation According to Genotype.

Authors:  Inseok Hwang; Je-Wook Park; Oh-Seok Kwon; Byounghyun Lim; Myunghee Hong; Min Kim; Hee-Tae Yu; Tae-Hoon Kim; Jae-Sun Uhm; Boyoung Joung; Moon-Hyoung Lee; Hui-Nam Pak
Journal:  Front Physiol       Date:  2021-05-13       Impact factor: 4.566

5.  In silico Assessment of Pharmacotherapy for Human Atrial Patho-Electrophysiology Associated With hERG-Linked Short QT Syndrome.

Authors:  Dominic G Whittaker; Jules C Hancox; Henggui Zhang
Journal:  Front Physiol       Date:  2019-01-11       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.